AbbVie (ABBV) Deferred Taxes (2019 - 2026)
AbbVie (ABBV) posted quarterly Deferred Taxes of $137.0 million for Q1 2026, up 589.29% year-over-year from $19.9 million in Q1 2025, and up 135.58% quarter-over-quarter from -$385.0 million in Q4 2025.
AbbVie (ABBV) Deferred Taxes (2019 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Deferred Taxes for 8 consecutive years, with $137.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Deferred Taxes rose 589.29% year-over-year to $137.0 million; the TTM figure through Mar 2026 stood at -$327.0 million (up 69.94% YoY), while the FY2025 annual figure was -$492.0 million, up 66.05% from the prior year.
- Deferred Taxes rose to $137.0 million in Q1 2026 per ABBV's latest filing, from -$385.0 million in the prior quarter.
- Across five years, Deferred Taxes topped out at $193.0 million in Q3 2025 and bottomed at -$1.4 billion in Q4 2023.
- Historically, Deferred Taxes has averaged -$389.6 million across 5 years, with a median of -$368.0 million in 2023.
- Annual changes were most pronounced in 2022 — Deferred Taxes slumped 1726.47% — and 2026, when it soared 589.29%.
- AbbVie's Deferred Taxes stood at -$516.0 million in 2022, then sank by 169.57% to -$1.4 billion in 2023, then surged by 44.86% to -$767.0 million in 2024, then jumped by 49.8% to -$385.0 million in 2025, then soared by 135.58% to $137.0 million in 2026.
- Business Quant data shows ABBV's Deferred Taxes at $137.0 million in Q1 2026, -$385.0 million in Q4 2025, and $193.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 648.02 Bn | 627.27 Bn | 17.26 Bn | -479.00 Mn |
| 2 | AbbVie | 467.00 Bn | 460.43 Bn | 12.70 Bn | -195.00 Mn |
| 3 | Merck | 373.58 Bn | 366.43 Bn | 12.21 Bn | -544.00 Mn |
| 4 | Novartis Ag | 299.43 Bn | 291.74 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 256.09 Bn | 251.19 Bn | 12.86 Bn | - |
| 6 | Amgen | 235.35 Bn | 221.36 Bn | 7.24 Bn | -291.00 Mn |
| 7 | Gilead Sciences | 179.91 Bn | 176.73 Bn | 6.22 Bn | -587.00 Mn |
| 8 | Pfizer | 159.32 Bn | 147.62 Bn | 10.94 Bn | -1.32 Bn |
| 9 | Gsk | 104.91 Bn | 100.74 Bn | 8.24 Bn | - |
| 10 | Sanofi | 54.69 Bn | 47.31 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -195.00 Mn |
| Mar 31, 2026 | 137.00 Mn |
| Dec 31, 2025 | -385.00 Mn |
| Sep 30, 2025 | 193.00 Mn |
| Jun 30, 2025 | -272.00 Mn |
| Mar 31, 2025 | -28.00 Mn |
| Dec 31, 2024 | -767.00 Mn |
| Sep 30, 2024 | -277.00 Mn |
| Jun 30, 2024 | -16.00 Mn |
| Mar 31, 2024 | -389.00 Mn |
| Dec 31, 2023 | -1.39 Bn |
| Sep 30, 2023 | -863.00 Mn |
| Jun 30, 2023 | -368.00 Mn |
| Mar 31, 2023 | -267.00 Mn |
| Dec 31, 2022 | -516.00 Mn |
| Sep 30, 2022 | -621.00 Mn |
| Jun 30, 2022 | -600.00 Mn |
| Mar 31, 2022 | -194.00 Mn |
| Dec 31, 2021 | -745.00 Mn |
| Sep 30, 2021 | -34.00 Mn |